Protalix BioTherapeutics Company Profile (NYSE:PLX)

Analyst Ratings

Consensus Ratings for Protalix BioTherapeutics (NYSE:PLX) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Protalix BioTherapeutics (NYSE:PLX)
Show:
DateFirmActionRatingPrice TargetActions
7/11/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Protalix BioTherapeutics (NYSE:PLX)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Protalix BioTherapeutics (NYSE:PLX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Protalix BioTherapeutics (NYSE:PLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Protalix BioTherapeutics (NYSE:PLX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Protalix BioTherapeutics (NYSE:PLX)
DateHeadline
05/22/16 11:38 PMNext Weeks Broker Price Targets For Protalix BioTherapeutics, Inc. (PLX) - Share Trading News - Next Weeks Broker Price Targets For Protalix BioTherapeutics, Inc. (PLX)Share Trading NewsProtalix BioTherapeutics, Inc. has a 50 day moving average of 0.84 and a 200 day moving average of 0.89. The stock's market capitalization is 79.74M, it has a 52-week low of 0.74 and a 52-week high of 2.20. The share price of the company (PLX) was up ...
05/20/16 07:03 PMThe Plaque Psoriasis (Psoriasis Vulgaris) Pipeline 2016 Market Report - MarketWatch - The Plaque Psoriasis (Psoriasis Vulgaris) Pipeline 2016 Market ReportMarketWatchCompanies discussed in this Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Review, H1 2016 report include 3SBio Inc., AbGenomics International, Inc., Almirall, S.A., Amgen Inc., AstraZeneca Plc, Avexxin AS, BIOCAD, Biocon Limited, Bionovis SA, ... Ltd ...and more »
05/20/16 07:03 PMBroker Roundup For Protalix BioTherapeutics, Inc. (PLX) - Share Trading News - Broker Roundup For Protalix BioTherapeutics, Inc. (PLX)Share Trading News05/13/2014 – Protalix BioTherapeutics, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 7 price target on the stock. The share price of Protalix BioTherapeutics, Inc. (PLX) was up +2.49% during the last trading ...
05/19/16 01:54 AMProtalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 19, 2016 -
05/19/16 12:19 AMProtalix BioTherapeutics Inc. Formed a Bearish Double Bottom, Could Be One of The Worst Performers Going Forward - Wall Street Hints and News - Protalix BioTherapeutics Inc. Formed a Bearish Double Bottom, Could Be One of The Worst Performers Going ForwardWall Street Hints and NewsThe chart of Protalix BioTherapeutics Inc. (PLX) shows a double bottom with $0.71 target or 12.00% below today's $0.81 share price. The 6 months chart pattern indicates high risk for the $316.03M company. It was reported on May, 19 by Finviz.com.
05/17/16 12:20 PMProtalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/09/16 06:59 AMProtalix reports 1Q loss -
05/09/16 06:16 AMProtalix BioTherapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - Advanced Discussions with FDA regarding SPA for Phase III Clinical Trial of PRX-102 Expected to Commence around Mid-Year Phase II Clinical Trial of PRX-110 in Cystic Fibrosis Patients to commence by Mid-Year ...
05/09/16 02:40 AMBroker Outlook For The Week Ahead Protalix BioTherapeutics, Inc. (PLX) - Share Trading News - Broker Outlook For The Week Ahead Protalix BioTherapeutics, Inc. (PLX)Share Trading NewsThe most recently updated broker views and price targets issued for Protalix BioTherapeutics, Inc. (PLX) are below. 04/04/2016 – Broker: Rodman & Renshaw Rating: buy New Target: 3.5 newcoverage. 03/16/2016 – Broker: Jefferies Rating: buy New Target: ...
05/07/16 06:36 PMProtalix Biotherapeutics Incorporated (NYSEMKT:PLX) Sellers Covered 11.98% of Their Shorts - B.O.D.Y Confidential - Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Sellers Covered 11.98% of Their ShortsB.O.D.Y ConfidentialThe short interest to Protalix Biotherapeutics Incorporated's float is 1.49%. The stock decreased 1.79% or $0.015 on May 6, hitting $0.8. About 19,845 shares traded hands. Protalix BioTherapeutics Inc. (NYSEMKT:PLX) has declined 28.57% since October 1, ...
04/28/16 01:50 AMProtalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorted Shares Decreased By 1.53% - B.O.D.Y Confidential - Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorted Shares Decreased By 1.53%B.O.D.Y ConfidentialThe short interest to Protalix Biotherapeutics Incorporated's float is 1.7%. The stock decreased 4.61% or $0.04 on April 27, hitting $0.83. About 43,723 shares traded hands. Protalix BioTherapeutics Inc. (NYSEMKT:PLX) has declined 41.96% since ...
04/22/16 09:37 PMProtalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorts Decreased by 1.53% After Short Covering - B.O.D.Y Confidential - Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorts Decreased by 1.53% After Short CoveringB.O.D.Y ConfidentialThe short interest to Protalix Biotherapeutics Incorporated's float is 1.7%. The stock decreased 1.65% or $0.014 on April 22, hitting $0.861. About 272,241 shares traded hands or 282.89% up from the average. Protalix BioTherapeutics Inc. (NYSEMKT:PLX) ...
04/19/16 09:36 PMLatest Analyst Ratings For Protalix BioTherapeutics, Inc. (PLX) - Share Trading News - Latest Analyst Ratings For Protalix BioTherapeutics, Inc. (PLX)Share Trading NewsProtalix BioTherapeutics, Inc. has a 50 day moving average of 0.87 and a 200 day moving average of 0.93. The stock's market capitalization is 82.67M, it has a 52-week low of 0.74 and a 52-week high of 2.35. The share price of the company (PLX) was up ...
04/14/16 09:53 PMBroker Outlook For Protalix BioTherapeutics, Inc. (PLX) - Share Trading News - Broker Outlook For Protalix BioTherapeutics, Inc. (PLX)Share Trading NewsAt the moment 4 analysts are watching Protalix BioTherapeutics, Inc. (PLX), 1 rate it “Buy”, 0 “Outperform”, 0 “Underperform”, 0 “Sell”, while 3 “Hold”. The most recently updated broker views and price targets issued for Protalix BioTherapeutics, Inc ...
04/14/16 01:46 AMProtalix Biotherapeutics Incorporated (NYSEMKT:PLX) Sellers Covered 6.08% of Their Shorts - Stock Caller - Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Sellers Covered 6.08% of Their ShortsStock CallerThe short interest to Protalix Biotherapeutics Incorporated's float is 1.72%. The stock increased 4.66% or $0.039 on April 13, hitting $0.88. About 87,544 shares traded hands or 40.57% up from the average. Protalix BioTherapeutics Inc. (NYSEMKT:PLX ...
04/12/16 08:57 PMProtalix BioTherapeutics, Inc. (PLX) Latest Broker Views - Risers & Fallers - Protalix BioTherapeutics, Inc. (PLX) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Protalix BioTherapeutics, Inc. (PLX). According to the latest broker reports outstanding on Tuesday 12th of April, 1 analyst has a rating of “strong buy”, 0 analysts ...
04/09/16 03:02 AMProtalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorted Shares Decreased By 6.08% - RiversideGazette.com - Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorted Shares Decreased By 6.08%RiversideGazette.comThe short interest to Protalix Biotherapeutics Incorporated's float is 1.72%. The stock increased 1.12% or $0.01 on April 8, hitting $0.9. About 73,519 shares traded hands or 29.33% up from the average. Protalix BioTherapeutics Inc. (NYSEMKT:PLX) has ...
04/08/16 09:53 PMProtalix BioTherapeutics, Inc. (PLX) Analyst Review - Risers & Fallers - Protalix BioTherapeutics, Inc. (PLX) Analyst ReviewRisers & FallersA number of investment brokers have recently updated their price targets on shares of Protalix BioTherapeutics, Inc. (PLX). According to the latest broker reports outstanding on Friday 8th of April, 1 analyst has a rating of “strong buy”, 0 analysts ...
04/08/16 04:01 PMPROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events -
04/05/16 08:24 PMProtalix BioTherapeutics, Inc. (PLX) Latest Broker Coverage - Risers & Fallers - The Vista VoiceProtalix BioTherapeutics, Inc. (PLX) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Protalix BioTherapeutics, Inc. (PLX). According to the latest broker reports outstanding on Tuesday 5th of April, 1 analyst has a rating of “strong buy”, 0 analysts ...Protalix BioTherapeutics Inc. (PLX) Now Covered by Analysts at Rodman & RenshawFinancial Market NewsProtalix BioTherapeutics Inc. (PLX) Coverage Initiated at Rodman & RenshawSouth Florida Hedge Fund ManagersProtalix BioTherapeutics Inc. (PLX) Now Covered by Rodman & RenshawThe Vista VoiceSmallCapWired.com -Los Angeles Mirrorall 10 news articles »
04/04/16 06:06 AMCoverage initiated on Protalix BioTherapeutics by Rodman & Renshaw -
04/02/16 07:35 PMMenora Mivtachim Holdings Ltd. Lowers stake in Protalix BioTherapeutics (PLX) - Street Edition - Menora Mivtachim Holdings Ltd. Lowers stake in Protalix BioTherapeutics (PLX)Street EditionOpaleye Management boosted its stake in PLX during the Q4 period, The investment management firm added 4,460,000 additional shares and now holds a total of 8,100,000 shares of Protalix BioTherapeutics which is valued at $7 Million. Protalix ...
04/01/16 07:59 PMUpgrades And Downgrades For Protalix BioTherapeutics, Inc. (PLX) - Risers & Fallers - Financial Market NewsUpgrades And Downgrades For Protalix BioTherapeutics, Inc. (PLX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Protalix BioTherapeutics, Inc. (PLX). The latest broker reports which are currently outstanding on Wednesday 30th of March state 1 analyst has a rating of “strong buy”, ...Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorted Shares Decreased By 6.08%RiversideGazette.comall 3 news articles »
04/01/16 07:59 PMCould Protalix BioTherapeutics Inc. Recover After Forming a Multiple Bottom Pattern? - RiversideGazette.com - Could Protalix BioTherapeutics Inc. Recover After Forming a Multiple Bottom Pattern?RiversideGazette.comThe stock of Protalix BioTherapeutics Inc. (PLX) shows a multiple bottoms pattern with $0.76 target or 10.00% below today's $0.84 share price. The 9 months chart pattern indicates high risk for the $303.61M company. It was reported on Apr, 2 by Finviz.com.
04/01/16 04:02 PMPROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, F -
03/28/16 06:56 PMAfter Last Week What Do Analysts Think Of Protalix BioTherapeutics, Inc. (PLX) - Share Trading News - After Last Week What Do Analysts Think Of Protalix BioTherapeutics, Inc. (PLX)Share Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of Protalix BioTherapeutics, Inc. (PLX). According to data from Reuters, 1 analyst has a rating of “buy”, 0 analysts “outperform”, 3 analysts “hold”, 0 ...
03/24/16 07:58 PMOpaleye Management buys $7 Million stake in Protalix BioTherapeutics (PLX) - Everything HUDSON - Opaleye Management buys $7 Million stake in Protalix BioTherapeutics (PLX)Everything HUDSONProtalix BioTherapeutics (PLX) : Opaleye Management scooped up 4,460,000 additional shares in Protalix BioTherapeutics during the Q4 period, according to a recent disclosure to the SEC. ... Protalix BioTherapeutics Inc. is a biopharmaceutical company.
03/24/16 07:58 PMProtalix Biotherapeutics Incorporated (NYSEMKT:PLX) Sellers Increased By 6.83% Their Shorts - Stock Caller - Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Sellers Increased By 6.83% Their ShortsStock CallerThe short interest to Protalix Biotherapeutics Incorporated's float is 1.83%. The stock increased 1.08% or $0.009 on March 24, hitting $0.849. About 12,261 shares traded hands. Protalix BioTherapeutics Inc. (NYSEMKT:PLX) has declined 48.47% since ...and more »
03/20/16 11:02 PMProtalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorted Shares Increased 6.83% After Market Selling - Clinton Financial - Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorted Shares Increased 6.83% After Market SellingClinton FinancialThe short interest to Protalix Biotherapeutics Incorporated's float is 1.83%. The stock decreased 2.81% or $0.025 on March 18, hitting $0.865. About 14,247 shares traded hands. Protalix BioTherapeutics Inc. (NYSEMKT:PLX) has declined 46.30% since ...Protalix BioTherapeutics, Inc. (PLX) Broker Views For Next WeekShare Trading Newsall 2 news articles »
03/16/16 08:46 PMProtalix BioTherapeutics Inc. (PLX) Given New $1.75 Price Target at Jefferies Group - MicroCap Magazine - Protalix BioTherapeutics Inc. (PLX) Given New $1.75 Price Target at Jefferies GroupMicroCap MagazineProtalix BioTherapeutics logo Protalix BioTherapeutics Inc. (AMEX:PLX) had its price objective cut by Jefferies Group from $2.30 to $1.75 in a research note issued to investors on Wednesday, StockTargetPrices.com reports. The brokerage presently has a ...
03/15/16 06:43 PMPrice Target Update On Protalix BioTherapeutics, Inc. (PLX) - Risers & Fallers - Price Target Update On Protalix BioTherapeutics, Inc. (PLX)Risers & Fallers05/13/2014 – Protalix BioTherapeutics, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 7 price target on the stock. The share price of Protalix BioTherapeutics, Inc. (PLX) was up +2.20% during the last trading ...
03/14/16 08:27 PMBig Movers: Protalix BioTherapeutics (NYSEMKT:PLX), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Pacific ... - KC Register - Big Movers: Protalix BioTherapeutics (NYSEMKT:PLX), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Pacific ...KC RegisterProtalix BioTherapeutics, Inc. (NYSEMKT:PLX) reported financial results for the 2015 fiscal year. Net Income of $85.3 million from discontinued operations for fiscal year 2015 includes a $40.0 million gain from the sale of the activity, recognition of ...
03/12/16 12:04 PMPROTALIX BIOTHERAPEUTICS, INC. Financials -
03/11/16 07:03 PMProtalix BioTherapeutics, Inc. (PLX) Broker Target Changes - Share Trading News - Protalix BioTherapeutics, Inc. (PLX) Broker Target ChangesShare Trading NewsAt the moment 4 analysts are watching Protalix BioTherapeutics, Inc. (PLX), 1 rate it “Buy”, 0 “Outperform”, 0 “Underperform”, 0 “Sell”, while 3 “Hold”. The most recently updated broker views and price targets issued for Protalix BioTherapeutics, Inc ...
03/10/16 07:23 PMProtalix BioTherapeutics, Inc. (PLX) New Analyst Ratings - Share Trading News - Protalix BioTherapeutics, Inc. (PLX) New Analyst RatingsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Protalix BioTherapeutics, Inc. (PLX). The latest reports which are currently in issue on Thursday 10th of March state 1 analyst has a rating of “strong buy”, 0 analysts ...
03/08/16 07:10 PMProtalix BioTherapeutics 2015 Revenue Rises, Net Loss Narrows, Sees Further Milestones in 2016 (NYSEMKT:PLX) - Sonoran Weekly Review - Protalix BioTherapeutics 2015 Revenue Rises, Net Loss Narrows, Sees Further Milestones in 2016 (NYSEMKT:PLX)Sonoran Weekly ReviewProtalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system ...Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate UpdateEconoTimesForm 8-K Protalix BioTherapeutics For: Mar 08StreetInsider.comall 7 news articles »
03/08/16 06:33 AMProtalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate Update - [GlobeNewswire] - Net Income of $58 Million Generated mainly due to the Sale of Our Share in Collaboration to Pfizer. Strong Cash Position of $76.3 Million Projected to Fund Operations into 2018. Special Protocol Assessment ...
03/03/16 06:06 PMProtalix BioTherapeutics (PLX) to Present Positive Interim Data from PRX-102 Phase 1/2 in Fabry Disease - StreetInsider.com - Protalix BioTherapeutics (PLX) to Present Positive Interim Data from PRX-102 Phase 1/2 in Fabry DiseaseStreetInsider.comProtalix BioTherapeutics, Inc. (NYSE: PLX) announced that positive interim data from the Company's phase I/II dose-ranging clinical trial of PRX-102 for the treatment of Fabry disease will be presented on March 3, 2016 at 3:15 PM PT at the Lysosomal ...Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment ...EconoTimesall 7 news articles »
03/03/16 11:28 AMProtalix Presents Positive Six And Twelve Month Interim Clinical Data On PRX-102 - (RTTNews.com) - Protalix BioTherapeutics, Inc. ( PLX) announced that positive interim data from the Company's phase I/II dose-ranging clinical trial of PRX-102 for the treatment of Fabry disease will be presented on March 3, 2016 at the Lysosomal Disease ...
03/03/16 06:07 AM7:07 am Protalix BioTherapeutics: 'positive' interim data from phase I/II dose-ranging clinical trial of PRX-102 to be presented on March 3 -
03/03/16 06:00 AMProtalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposium™ 2016 - [GlobeNewswire] - Demonstrated Effectiveness Across All Disease Parameters Including Cardiac and Kidney Functions. PRX-102 Safe and Well Tolerated With Very Low Formation of Antibodies. CARMIEL, Israel, March 03, 2016-- ...
03/02/16 11:16 AMProtalix BioTherapeutics, Inc. (PLX) Broker Updates - Risers & Fallers - Protalix BioTherapeutics, Inc. (PLX) Broker UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Protalix BioTherapeutics, Inc. (PLX). According to the latest broker reports outstanding on Tuesday 1st of March, 1 analyst has a rating of “strong buy”, 0 analysts ...Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Short Interest Increased By 2.39%SmallCapWired.comProtalix BioTherapeutics Inc. (PLX) Upgraded at Zacks Investment ResearchFinancial Market Newsall 2 news articles »
02/26/16 06:11 PMProtalix Biotherapeutics Incorporated (NYSEMKT:PLX) Sellers Covered 6.22% of Their Shorts - Franklin Independent - Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Sellers Covered 6.22% of Their ShortsFranklin IndependentThe short interest to Protalix Biotherapeutics Incorporated's float is 1.62%. The stock decreased 0.59% or $0.005 on February 25, hitting $0.81. About 42,327 shares traded hands. Protalix BioTherapeutics Inc. (NYSEMKT:PLX) has declined 53.11% since ...
02/22/16 10:35 AMProtalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorted Shares Decreased By 6.22% - Franklin Independent - Protalix Biotherapeutics Incorporated (NYSEMKT:PLX) Shorted Shares Decreased By 6.22%Franklin IndependentThe short interest to Protalix Biotherapeutics Incorporated's float is 1.62%. The stock decreased 3.62% or $0.03 on February 19, hitting $0.797. About 35,278 shares traded hands. Protalix BioTherapeutics Inc. (NYSEMKT:PLX) has declined 58.12% since ...Protalix BioTherapeutics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual ...GlobeNewswire (press release)all 4 news articles »
02/22/16 06:30 AMProtalix BioTherapeutics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposium™ 2016 - [GlobeNewswire] - CARMIEL, Israel, Feb. 22, 2016-- Protalix BioTherapeutics, Inc. and, announced today that the Company will participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12 th Annual WORLD Symposium ...
02/17/16 05:03 PMCould Protalix BioTherapeutics Inc. Go Down? The Stock Formed Bearish Multiple Bottom Pattern - Sonoran Weekly Review - Could Protalix BioTherapeutics Inc. Go Down? The Stock Formed Bearish Multiple Bottom PatternSonoran Weekly ReviewThe stock of Protalix BioTherapeutics Inc. (PLX) shows a multiple bottoms pattern with $0.74 target or 10.00% below today's $0.83 share price. The 5 months chart pattern indicates high risk for the $326.78 million company. It was reported on Feb, 17 by ...and more »
02/16/16 09:52 AMProtalix BioTherapeutics, Inc. (PLX) Price Target Changes - Risers & Fallers - Protalix BioTherapeutics, Inc. (PLX) Price Target ChangesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Protalix BioTherapeutics, Inc. (PLX). According to the latest broker reports outstanding on Tuesday 16th of February, 1 analyst has a rating of “strong buy”, 0 ...
02/06/16 09:28 AMProtalix BioTherapeutics Inc.'s Stock Is Sell After Forming Bearish Double Bottom Chart Pattern - Sonoran Weekly Review - Protalix BioTherapeutics Inc.'s Stock Is Sell After Forming Bearish Double Bottom Chart PatternSonoran Weekly ReviewThe chart of Protalix BioTherapeutics Inc. (PLX) shows a double bottom with $0.72 target or 14.00% below today's $0.84 share price. The 7 months chart pattern indicates high risk for the $311.60M company. It was reported on Feb, 5 by Finviz.com. If the ...
01/24/16 08:35 AMProtalix BioTherapeutics, Inc. (PLX) - 23-Nov-15 PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits 16-Nov-15 PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events 9-Nov-15 PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K ...
01/04/16 03:31 PMPROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Shareholder Director Nominations -

Social

About Protalix BioTherapeutics

No company description available

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: PLX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $
  • 200 Day Moving Average: $
  • P/E Ratio:
  • P/E Growth:
  • Market Cap: $
  • Current Year EPS Consensus Estimate: $-0.33 EPS
  • Next Year EPS Consensus Estimate: $-0.29 EPS
Additional Links:
Protalix BioTherapeutics (NYSE:PLX) Chart for Saturday, July, 30, 2016